---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-070826"
form_type: "8-K"
ticker: "CLRB"
cik: "0001279704"
company_name: "Cellectar Biosciences, Inc."
filed_at: "2023-06-13T23:59:59+00:00"
generated_at: "2026-06-14T01:52:04.209393+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Cellectar delays WM pivotal trial top-line data to H2 2023; pediatric glioma trial to start Q3

## Summary
- Top-line data from WM CLOVER-WaM trial delayed to H2 2023; 2024 product launch still targeted.
- All 49 sites now active; enrollment accelerated after initial delays from site contracting and regulatory responses.
- Plans to initiate Phase 1b study in pediatric high-grade gliomas in Q3 2023, supported by $2M NCI grant.
- Iopofosine I 131 showed 100% ORR, 83.3% major response rate in Phase 2a WM study (6 patients).
- Fast Track Designation allows 6-month FDA review; platform expands to alpha-emitter, siRNA, and peptide payloads.

## SEC filing metadata
- accession: 0001104659-23-070826
- form_type: 8-K
- ticker: CLRB
- cik: 0001279704
- company_name: Cellectar Biosciences, Inc.
- filed_at: 2023-06-13T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1279704/000110465923070826/0001104659-23-070826-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1279704/000110465923070826/tm2318538d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-070826
- JSON: https://secwatch.observer/filing/0001104659-23-070826.json
- Plain text: https://secwatch.observer/filing/0001104659-23-070826.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.